 "Aurobindo Pharma receives US FDA nod for pain killer and epilepsy drug")
Aurobindo Pharma has received US Food & Drug Administration (USFDA) approval for a pain killer (celecoxib capsule) and an epilepsy drug (levetiracetam injection).
The company received final approval from the US FD to manufacture and market celecoxib capsule (in strengthens 50 mg, 100 mg, 200 mg, and 400 mg). This product is expected to be launched in Q4 FY15-16. Celecoxib capsule, which is generic version of Searle Llc’s Celebrex, has an estimated market size of $ 976 million for the twelve months ending November 2015, according to IMS.
Celecoxib capsule is used in the treatment of pain and inflammation of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis (2 years and older) ankylosing spondylitis, acute pain in adults, primary dysmenorrhea.
US FDA also granted final approval for Aurobindo Pharma’s levetiracetam injection, 500 mg/5 mL (100 mg/mL) single-dose vial, a generic version of UCB’s Keppra injection. Levetiracetam injection is used for the treatment of partial onset seizures, myoclonic seizures in patients with juvenile myoclonic epilepsy, and primary generalised tonic-clonic seizures. The approved product has an estimated market size of $ 29 million for the twelve months ending November 2015, according to IMS.
The company received final approval from the US FD to manufacture and market celecoxib capsule (in strengthens 50 mg, 100 mg, 200 mg, and 400 mg). This product is expected to be launched in Q4 FY15-16. Celecoxib capsule, which is generic version of Searle Llc’s Celebrex, has an estimated market size of $ 976 million for the twelve months ending November 2015, according to IMS.
Celecoxib capsule is used in the treatment of pain and inflammation of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis (2 years and older) ankylosing spondylitis, acute pain in adults, primary dysmenorrhea.
US FDA also granted final approval for Aurobindo Pharma’s levetiracetam injection, 500 mg/5 mL (100 mg/mL) single-dose vial, a generic version of UCB’s Keppra injection. Levetiracetam injection is used for the treatment of partial onset seizures, myoclonic seizures in patients with juvenile myoclonic epilepsy, and primary generalised tonic-clonic seizures. The approved product has an estimated market size of $ 29 million for the twelve months ending November 2015, according to IMS.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%